No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target ...

NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.

Doudna codeveloped the revolutionary gene-editing technology known as CRISPR-Cas9. Now it’s leading to cures to some of the ...

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline ...

The researchers first compared 4 gene-editing platforms to establish SF3B1 mutant cell lines: CRISPR-Cas9 editing, AAV HDR editing, base editing and prime editing. Prime editing was shown to be more ...

ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor ... 2 registrational study for first-line consolidation therapy in large B-cell lymphoma [LBCL].

In a new study published in the Journal of Cell Science, Associate Professor at the Department of Biochemistry, Sandeep ...

Let's consider two candidates along those lines ... discovery CRISPR Therapeutics is a mid-cap biotech company founded in 2013. It develops gene-editing medicines using CRISPR/Cas9, a technique ...